<DOC>
	<DOC>NCT00503711</DOC>
	<brief_summary>An open, phase 1 to assess the PK of rising doses of ZD6474 when administered daily in Chinese patients with advanced solid malignant tumors.</brief_summary>
	<brief_title>Phase I Chinese PK</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>histological and/or cytological confirmation of a malignant solid tumor refractory to standard therapies or for which no appropriate therapies exist WHO performance status 02 patients with brain tumors or symptomatic cerebral metastases systemic anticancer therapy within the last 4 weeks</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>ZD6474 PK</keyword>
</DOC>